We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urinary Biomarkers Associated with Kidney Disease Risk Factors

By LabMedica International staff writers
Posted on 14 Jan 2019
Print article
Image: The BN II Nephelometer System is an easy-to-use, reliable nephelometric analyzer that offers a broad range of protein assays (Photo courtesy of Siemens Healthcare).
Image: The BN II Nephelometer System is an easy-to-use, reliable nephelometric analyzer that offers a broad range of protein assays (Photo courtesy of Siemens Healthcare).
The improved life expectancy among treated human immunodeficiency virus (HIV)-positive patients has been tempered by the excess burden of age-related non-infectious co-morbidities, including chronic kidney disease (CKD).

In this HIV-positive population, CKD results not only from traditional risk factors, such as diabetes and hypertension, but also from HIV-related risk factors, including uncontrolled viremia, chronic co-infection with hepatitis C virus (HCV), and exposure to potentially nephrotoxic antiretroviral (ART) medications.

Scientists at the San Francisco Veterans Affairs Medical Center (San Francisco, CA, USA) and their colleagues carried out a cross-sectional study of HIV-positive persons in the Multicenter AIDS Cohort Study and the Women’s Interagency HIV Study. Of the 198 participants, one third were on HAART and virally suppressed. The team evaluated associations of known CKD risk factors with urine biomarkers using separate multivariable adjusted models for each biomarker.

The scientists measured levels of 14 urine biomarkers in clean catch urine specimens that were collected prospectively, refrigerated immediately after collection, and subsequently centrifuged. Each hypothesized urine biomarker was to indicate a distinct dimension of kidney injury and dysfunction. All urine biomarkers were measured using multiplex immunoassays from Meso Scale Discovery (MSD, Rockville, MD, USA), except urine creatinine which was measured using the Roche enzymatic creatinine assay and α1-microglobulin (α1m), which was measured using a commercial assay.

The team reported that the vast majority (95%) had preserved kidney function as assessed by serum creatinine, with a median eGFR of 103 mL/min/1.73 m2. In the multivariable analyses, the associations of each CKD risk factor with urinary biomarker levels varied in magnitude. For example, HIV viral load was predominantly associated with elevations in interleukin (IL)-18, and albuminuria, while higher CD4 levels were associated with lower monocyte chemoattractant protein-1 (MCP-1) and β2-microglobulin. In contrast, older age was significantly associated with elevations in α1-microglobulin, kidney injury marker-1, clusterin, MCP-1, and chitinase-3-like protein-1 levels, as well as lower epidermal growth factor, and uromodulin levels.

The authors concluded that among HIV-positive persons, CKD risk factors are associated with unique and heterogeneous patterns of changes in urine biomarkers levels. The findings highlight the potential clinical utility of routine measurement of multiple biomarker levels. Additional work is needed to develop parsimonious algorithms that integrate multiple biomarkers and clinical data to discern the risk of overt CKD and its progression. The study was published on January 3, 2019, in the journal BMC Nephrology.

Related Links:
San Francisco Veterans Affairs Medical Center
Meso Scale Discovery

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.